InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

This phase III study is comparing the effectiveness of two types of immunotherapy treatments (MK-7684A and atezolizumab) when used in combination with chemotherapy (etoposide and carboplatin or cisplatin) in people with Extensive-Stage Small Cell Lung CancerA Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer

Clinical summary

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200mg pembrolizumab and 200mg vibostolimab (also known as MK7684A) every 3 weeks, in combination with 100mg/m^2 etoposide, and platinum chemotherapy (Area Under the Curve [AUC] 5 mg/mL/min carboplatin or 75mg/m^2 cisplatin)every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of MK7684A every 3 weeks. In the Active Comparator Arm, participants will receive 4 cycles (each cycle is 3 weeks) of 1200mg atezolizumab every 3 weeks, in combination with 100mg/m^2 etoposide and platinum chemotherapy (AUC 5mg/mL/min carboplatin or 75mg/m^2 cisplatin) every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of atezolizumab every 3 weeks.

Age

People18+

Phase

III

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Merck

Scientific Title

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more